| Authors: |
Moreira S; Clinical Pharmacology Modeling & Simulation, GSK, Collegeville, Pennsylvania, USA sebastian.a.moreira@gsk.com., Clow L; Respiratory, Immunology & Inflammation Research Unit Medicine Development Leaders, GSK, Stevenage, UK., Coles-Piper E; Global Clinical Operations Development - R&D, GSK, London, UK., Donald A; Development Biostatistics, GSK, Upper Providence, Pennsylvania, USA., Janson C; Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden., Singh D; Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK.; Medicines Evaluation Unit, Manchester, UK., Slade D; Respiratory Clinical Research Unit, GSK, Collegeville, Pennsylvania, USA., Tiwari P; Statistics (R&D), GSK, Bengaluru, Karnataka, India., Weng S; Respiratory Biostatistics, GSK, Stevenage, UK., Plank M; Global Medical Affairs, General Medicines, GSK, Gold Coast, Queensland, Australia. |
